Discussion of Treatment Options for Acute Myelogenous Leukemia (AML)
Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals discusses treatment options for acute myelogenous leukemia (AML), which comprise a variety of chemotherapy regimens and stem cell transplantation. Current standard chemotherapy regimens cure only a minority of patients with AML. As a result, all patients should be evaluated for entry into well-designed clinical trials. Actinium’s Iomab-B is intended to be an induction and conditioning agent prior to a bone marrow transplant (BMT), often referred to as a hematopoietic stem cell transplant (HSCT) with an initial indication in patients with relapsed or refractory acute myeloid leukemia (AML) who are age 55 and above.